Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2553 • ACR Convergence 2024
Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study
Mark Russell¹, Mark Gibson², Benjamin Zuckerman¹, Kanta Kumar³, Shirish Dubey⁴, Maryam Adas², Edward Alveyn², Samir Patel¹, Zijing Yang¹, Katie Bechman², Elizabeth Price⁵, Sarah Gallagher⁶, Andrew Cope², Sam Norton¹ and James Galloway⁷, ¹King's College London, London, England, United Kingdom, ²King's College London, London, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴Oxford University Hospitals NHS FT, Oxford, United Kingdom, ⁵Great Western Hospital NHS Foundation Trust, Swindon, England, United Kingdom, ⁶British Society for Rheumatology, London, United Kingdom, ⁷Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Quantifying healthcare inequality is essential to addressing the imbalance in outcomes attributable to age, gender, ethnicity and multimorbidity. In this study, we analysed differences…
Abstract Number: 2673 • ACR Convergence 2024
Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis
Diane Lacaille¹, Coraline Danieli², Kasra Moolooghy¹ and Michal Abrahamowicz³, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC, Canada, ³McGill University, Verdun, Canada
Background/Purpose: Glucocorticosteroid (GC) use is associated with increased mortality risk, especially from cardiovascular diseases (CVD) and infections, with dose and duration of use influencing risk.…
Abstract Number: 0045 • ACR Convergence 2024
Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins
Khushali Trivedi¹, Clarissa Klenke², Jun Kim¹, Jeba Atkia Maisha², Alina Sememenko¹, XIAOBO MENG², Mario Navarrete¹, Hani El-Gabalawy² and Liam O'Neil², ¹University of Manitoba, Winnipeg, Canada, ²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
Abstract Number: 0063 • ACR Convergence 2024
Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils
Rayan Najjar¹, Noga Rogel² and Tomas Mustelin³, ¹University of Washington, Seattle, ²University of Washinton, Seattle, ³University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by a variable response to therapies, reflecting its complex and incompletely understood pathogenesis. Emerging research suggests…
Abstract Number: 0152 • ACR Convergence 2024
Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases
Janett Riega Torres¹, Karina Palomo-Arnaud², Gabriel Figueroa-Parra¹, Fernando Morales Wong¹, Jesús Hernán González Cortés¹, Jesus Mohamed Hamsho¹, Jorge Esquivel-Valerio¹, Dionicio Galarza-Delgado³ and Karim Mohamed Noriega¹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ³UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology. Retinal toxicity is an unwanted side effect…
Abstract Number: 0232 • ACR Convergence 2024
Subjective and Objective Measures of Disease Activity in Difficult-to-Treat Rheumatoid Arthritis Patients at Baseline and Follow-up After an Advanced Therapy: An Ultrasound Study
Seyyid Bilal Acikgoz¹, Ricardo Sabido-Sauri², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel², Sylvia Sangwa⁴, Elliot Hepworth² and Sibel Aydin⁵, ¹University of Ottawa, Rheumatology, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increasing number of patients with rheumatoid arthritis (RA) who have been failed by multiple therapies,…
Abstract Number: 0427 • ACR Convergence 2024
Association of Menopause and Systemic Rheumatic Disease Severity in Peri-Menopausal and Menopausal Women with Systemic Rheumatic Disease
Lucy Masto¹, Amaya Smole², Ranqing Lan¹, Michael Parides¹, Caroline Siegel¹, Sarah Lieber¹, Jonah Levine¹, Bessie Stamm¹, Lisa Mandl¹, Michael Lockshin³, Lisa Sammaritano⁴ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Amherst, MA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, Scarsdale, NY
Background/Purpose: The relationship between menopause and systemic rheumatic disease (SRD) severity in women with SRDs is poorly understood. Few studies evaluating this association suggest worsening…
Abstract Number: 0466 • ACR Convergence 2024
Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample
Karun Shrestha¹, Prakriti Subedi², Manoj Ghimire³, Sajana Poudel⁴, Keerthi Parvathaneni⁵, Mahmoud Hashim⁶, Kalpana Ghimire⁵, Oshna Pandey⁵, Mohammed Hasan⁷, Clement Tagoe⁸ and Liliya Gandrabur⁹, ¹St. Barnabas Hospital Internal Medicine Residency, Bronx, NY, ²St. Barnabas Hospital, Bronx, NY, ³St Barnabas Hospital, BRONX, NY, ⁴Cook County Health, CHICAGO, NY, ⁵Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY 10457, USA, Bronx, NY, ⁶SBH Health System, New Rochelle, NY, ⁷Parkview Medical Center, Pueblo, CO, ⁸Albert Einstein College of Medicine, FRESH MEADOWS, NY, ⁹SBH Health System, Forest Hills, NY
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) treatment, effective pain management remains challenging, with many patients also experiencing insomnia, anxiety, and depression. As cannabis legalization…
Abstract Number: 0483 • ACR Convergence 2024
Obesity, Prednisone Use, and Patient-Reported Outcomes Are Predictors of Becoming Difficult-to-Treat in an RA Population Treated with a First-Line Biologic DMARD
Misti Paudel¹, Shravani Chitineni¹, Ruogu Li², Chinmayi Naik³, Nancy Shadick³, Michael Weinblatt⁴ and Daniel Solomon⁵, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Prior studies have evaluated the risk factors for difficult-to-treat RA (D2T-RA) but have not applied EULAR’s full criteria for D2T-RA in a longitudinal data…
Abstract Number: 0500 • ACR Convergence 2024
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years
Kevin Winthrop¹, Daniel Aletaha², Roberto Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Vikas Modgill⁶, Edmund V. Ekoka Omoruyi⁷, Dick de Vries⁸, Katrien Van Beneden⁹, Jacques-Eric Gottenberg¹⁰ and Gerd Burmester¹¹, ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Clinical Development, Galapagos BV, Leiden, Netherlands, ⁹Medical Affairs, Galapagos NV, Mechelen, Belgium, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The oral Janus kinase 1-preferential inhibitor filgotinib (FIL) is approved at doses of 100 mg (FIL100) and 200 mg (FIL200) for the treatment of…
Abstract Number: 0516 • ACR Convergence 2024
Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old
Bruno Fautrel¹, Alain SARAUX², Isabelle Idier³, Henri Bonnabau⁴, Geoffray Bizouard⁵ and BERNARD COMBE⁶, ¹INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ²CHU Brest, Brest, France, ³Chugai Pharma france, Puteaux, Ile-de-France, France, ⁴IQVIA France, Bordeaux, France, ⁵IQVIA France, La Defense, Ile-de-France, France, ⁶Montpellier University, LA GRANDE MOTTE, Languedoc-Roussillon, France
Background/Purpose: Few real-life long-term data are available in RA patients initiating tocilizumab (TCZ) depending on age. The objective of this study was to compare the…
Abstract Number: 0534 • ACR Convergence 2024
Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis
Alexandre Matar¹, Maya Breitman², Tracey Bonfield³, Maricela Haghiac⁴, Jane Reese³, Emma Barnboym⁵, Steven Lewis⁶, Hillard Lazarus⁷ and Nora Singer⁸, ¹MetroHealth, Westlake, OH, ²MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Metrohealth Medical Center, Cleveland, OH, ⁵The MetroHealth System, Cleveland, OH, ⁶Case Western University, MetroHealth, Cleveland, OH, ⁷Case Western Reserve University/University Hospitals, Cleveland, OH, ⁸MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Mesenchymal stem (stromal) cells (MSCs) constitute an emerging therapeutic strategy for several human diseases. Small non-randomized studies have shown that MSCs may be a…
Abstract Number: 0850 • ACR Convergence 2024
Assessment of Correlation Between Composite Ultrasonographic Index (ECODAS) and Disease Activity Score 28 in Patients with Rheumatoid Arthritis
Komal Verma Saluja¹, Harshvardhan Khokhar², Amit Sharma³ and Saurabh Chittora², ¹Government Medical college Kota, Kota, Rajasthan, India, ²Government Medical college Kota, Kota, India, ³Fortis hospital Jaipur, Jaipur, India
Background/Purpose: Conventional Disease Activity Score 28 has variable sensitivity, subjectivity, inherent bias due to certain variables such as more weightage to joint tenderness and overestimation…
Abstract Number: 0906 • ACR Convergence 2024
Proteomic Signatures of Difficult-to-Treat Rheumatoid Arthritis: Identifying Predictive Biomarkers
Klára Mocová¹, Jiri Baloun¹, Aneta Prokopcová², Kristýna Brábníková Marešová¹, Herman Mann³, Jiří Vencovský², Karel Pavelka⁴ and Ladislav Šenolt², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Revmatologický ústav, Praha, Czech Republic, ⁴Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction and extra-articular manifestations. Despite the advancements in the…
Abstract Number: 0974 • ACR Convergence 2024
Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data
Abhishek Abhishek¹, Nicholas Peckham² and Jonathan Cook², and the VROOM Study Author Group, ¹University of Nottingham, Nottingham, United Kingdom, ²Oxford University, Oxford, United Kingdom
Background/Purpose: Immunosuppression attenuates immune response to vaccination. A 2-week interruption in low-dose weekly methotrexate immediately after COVID-19 booster improved antibody response to vaccination. There is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].